v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
REVENUES:    
Product revenue $ 16,012,910 $ 10,164,036
License revenue 35,708 35,708
Total revenues 16,048,618 10,199,744
OPERATING EXPENSES:    
Cost of product revenue (exclusive of amortization expense shown below) 17,770,122 16,829,226
Research and development 987,649 1,528,738
Plasma center operating expenses 2,242,343 500,644
Amortization of intangible assets 178,838 178,838
Selling, general and administrative 10,033,915 7,932,084
Total operating expenses 31,212,867 26,969,530
LOSS FROM OPERATIONS (15,164,249) (16,769,786)
OTHER INCOME (EXPENSE):    
Interest income 22,059 248,068
Interest expense 3,195,750 2,717,091
Other expense (42,001) (6,421)
Other expense, net (3,215,692) (2,475,444)
NET LOSS $ (18,379,941) $ (19,245,230)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.16) $ (0.26)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic and Diluted 115,661,937 73,781,507

Source